According to a report released by the US Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO), the three most common types of influenza strains have changed in such a way that they are now showing signs of resistance to the Tamiflu and Relenza vaccines
According to a report released by the US Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO), the three most common types of influenza strains have changed in such a way that they are now showing signs of resistance to the Tamiflu and Relenza vaccines.
For the first time in 20 years, the CDC is recommending a complete reformulation of the vaccine. In its FluView report for the week ending March 1, the CDC announced its recommendations for the formulation of the influenza vaccine for the 2008-2009 flu season. The recommendations are announced a year in advance because of the lengthy process by which the vaccines are produced. All three of the inactivated strains of the virus that were suggested for the 2008-2009 formulation are different from the current formulation.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Filter Sizing for Process Optimization in Life Sciences Sterile Filtration
April 24th 2025Bench-scale filterability studies play a critical role in optimizing sterile filtration in biopharmaceutical manufacturing. By guiding the selection and sizing of filters, these studies help streamline processes, improve scalability, and reduce costs. Through data-driven case studies, this paper highlights how the strategic use of pre-filters and membrane materials can maximize throughput and minimize filter fouling.
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.